This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Leukaemia of unspecified cell type
CD2_LEUKAEMIA_NAS
leukemia: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
340 |
4. Check minimum number of eventsNone |
340 |
5. Include endpointsNone |
340 |
6. Filter based on genotype QC (FinnGen only) |
314 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF8
- Parent code in ICD-10
- C81-C96
- Name in latin
- Leuc(h)aemiae typo cellulari non specificato
Similar endpoints
↥List of similar endpoints to
Leukaemia of unspecified cell type
based on the number of shared cases.
Similar with more cases:
- Primary_lymphoid and hematopoietic malignant neoplasms
- Liquid cancers, helper endpoint
- Malignant neoplasm
- Malignant neoplasm, wide definition for exclusion
- Neoplasms
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 314 | 138 | 176 |
| Unadjusted period prevalence (%) | 0.07 | 0.05 | 0.08 |
| Median age at first event (years) | 64.14 | 59.39 | 67.87 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 340
- Matched controls
- 3400
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
59.5
318.8
211
91
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
241.5
202
*
XW000
NOMESCO Finland
Bone marrow biopsy
43.1
241.4
164
72
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
331.7
132.2
126
6
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
26.7
115.4
85
42
C95.9
ICD-10 Finland
Leukaemia, unspecified
1386.7
107.5
99
*
WW500
NOMESCO Finland
Blood transfusion
17.3
106.5
99
79
L03AA02
ATC
filgrastim; parenteral
18.9
82.6
70
46
L01BB02
ATC
mercaptopurine; oral
42.8
78.4
48
13
A05AA02
ATC
ursodeoxycholic acid; oral
30.0
71.8
49
19
127
Kela drug reimbursment
Transplant complication
32.3
67.8
45
16
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
372.3
62.6
61
*
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
151.0
60.1
62
5
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
29.0
59.7
41
16
A04AA01
ATC
ondansetron; systemic, rectal
8.2
56.4
88
139
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
24.3
53.3
39
18
M04AA01
ATC
allopurinol; systemic
6.0
51.7
122
291
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
8.5
51.4
75
109
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.9
47.9
112
263
J05AB11
ATC
valaciclovir; oral
5.3
42.0
111
287
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.9
36.7
63
108
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
206.8
36.5
37
*
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
75.2
35.8
40
6
C95.1
ICD-10 Finland
Chronic leukaemia of unspecified cell type
+∞
35.0
33
*
9835/3-C42.1
ICD-O-3
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
133.7
34.4
36
*
ZX120
NOMESCO Finland
Intravenous
5.4
33.6
78
178
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
9.3
31.5
40
48
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
11.7
30.9
33
31
TAB00
NOMESCO Finland
Lumbar puncture
7.6
30.1
46
69
A41.9
ICD-10 Finland
Sepsis, unspecified
8.1
30.0
43
60
H02AB09
ATC
hydrocortisone; systemic
10.4
29.3
34
36
R50.9
ICD-10 Finland
Fever, unspecified
4.1
29.0
104
332
WW200
NOMESCO Finland
Immunization
10.9
28.7
32
32
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.5
28.6
83
226
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.8
26.4
103
346
D64.9
ICD-10 Finland
Anaemia, unspecified
4.3
26.0
79
222
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
37.7
24.7
31
9
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
245.9
22.9
23
*
189
Kela drug reimbursment
Imatinib
128.7
22.9
24
*
L01XX05
ATC
hydroxycarbamide; oral
18.1
21.4
33
20
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
5.6
21.3
43
85
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
20.9
201
1121
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
117.3
20.8
22
*
J01MA12
ATC
levofloxacin; systemic
3.2
19.3
102
407
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
6.2
18.9
34
60
L04AD01
ATC
ciclosporin; systemic
16.3
18.8
30
20
B73
ICPC
Leukaemia
200.6
18.7
19
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
7.4
18.1
27
39
J02AC03
ATC
voriconazole; systemic
44.7
17.5
21
5
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
44.7
17.5
21
5
H02AB02
ATC
dexamethasone; systemic
3.7
17.3
62
193
121
Kela drug reimbursment
Severe hypofunction of sexual glands
16.2
17.0
27
18
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
19.2
16.7
25
14
L01XE01
ATC
[U] imatinib
94.8
16.7
18
*
JN4AD
NOMESCO Finland
Body CT examination
3.7
15.9
57
177
Z85.6
ICD-10 Finland
Personal history of leukaemia
+∞
15.7
15
*
9801/3-C42.1
ICD-O-3
Acute leukemia, NOS, of bone marrow
+∞
15.7
15
*
ZXD05
NOMESCO Finland
Urgent procedure
2.6
15.6
136
696
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
6.7
15.2
25
40
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
4.9
14.8
34
75
J02AC04
ATC
posaconazole; systemic
+∞
14.7
14
*
212
Kela drug reimbursment
Gout
7.1
14.2
22
33
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
21.2
13.9
20
10
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.5
13.9
36
88
L01EA01
ATC
imatinib; oral
78.4
13.7
15
*
316
Kela drug reimbursment
Imatinib
+∞
13.6
13
*
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
13.6
13
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
13.6
13
*
TPH00
NOMESCO Finland
Phlebotomy
52.1
12.9
15
*
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
16.3
12.8
20
13
C92.5
ICD-10 Finland
Acute myelomonocytic leukaemia
+∞
12.6
12
*
J05AB01
ATC
aciclovir; systemic
2.5
11.9
95
457
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
4.8
11.9
28
63
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
31.3
11.7
15
5
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
23.9
11.7
16
7
C92.4
ICD-10 Finland
Acute promyelocytic leukaemia [PML]
+∞
11.5
11
*
N02AA05
ATC
oxycodone; systemic
2.5
11.4
85
396
ZX121
NOMESCO Finland
Central venous catheter
26.0
11.2
15
6
J01MA14
ATC
moxifloxacin; systemic
3.1
11.2
50
177
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.3
10.7
107
566
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.3
10.6
28
69
9863/3-C42.1
ICD-O-3
Chronic myeloid leukemia, NOS, of bone marrow
113.4
10.5
11
*
9811/3-C42.1
ICD-O-3
B lymphoblastic leukemia/lymphoma, NOS, of bone marrow
+∞
10.5
10
*
2089X
ICD-9 Finland
Leukaemia of unspecified cell type, Unspecified leukaemia
+∞
10.5
10
*
152
Kela drug reimbursment
Nilotinib
+∞
10.5
10
*
Z51.5
ICD-10 Finland
Palliative care
3.2
10.3
44
152
ZX131
NOMESCO Finland
Intrathecal
56.7
9.7
11
*
150
Kela drug reimbursment
Dasatinib
102.8
9.5
10
*
9800/3-C42.1
ICD-O-3
Leukemia, NOS, of bone marrow
+∞
9.4
9
*
L04AX03
ATC
methotrexate; systemic
3.0
9.3
44
161
A41.1
ICD-10 Finland
Sepsis due to other specified staphylococcus
16.2
9.1
14
9
ZX090
NOMESCO Finland
Other technic of radiotherapy
4.7
9.0
21
47
L04AA01
ATC
[U] ciclosporin
13.0
8.9
15
12
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
16.8
8.6
13
8
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
20.7
8.5
12
6
JN4BD
NOMESCO Finland
Extensive body CT
2.6
8.3
51
214
H02AB04
ATC
methylprednisolone; systemic
2.4
8.2
60
274
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
17.7
8.1
12
7
D70.89
ICD-10 Finland
Neutropenic splenomegaly
9.3
8.1
16
18
C90.0
ICD-10 Finland
Multiple myeloma
9.3
8.1
16
18
SPAT1074
SPAT
Venesection
22.7
8.1
11
5
L01BA01
ATC
methotrexate; systemic
4.6
8.0
19
43
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
3.2
7.7
31
103
C91.9
ICD-10 Finland
Lymphoid leukaemia, unspecified
25.7
7.6
10
*
5BA08, ,
NOMESCO Finland
25.7
7.6
10
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
7.5
48
205
A41.8
ICD-10 Finland
Other specified sepsis
6.7
7.5
18
28
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
7.9
7.5
16
21
L01XE06
ATC
[U] dasatinib
81.8
7.4
8
*
2AA01, ,
NOMESCO Finland
81.8
7.4
8
*
ZX114
NOMESCO Finland
Intramuscular
8.7
7.4
15
18
L01XE08
ATC
[U] nilotinib
+∞
7.3
7
*
C93.0
ICD-10 Finland
Acute monoblastic/monocytic leukaemia
+∞
7.3
7
*
WW304
NOMESCO Finland
Transfer of stem cells from registered domestic donator
+∞
7.3
7
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
16.2
7.3
11
7
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.4
7.3
26
80
D61.9
ICD-10 Finland
Aplastic anaemia, unspecified
30.7
7.2
9
*
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.9
7.1
139
916
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.9
7.1
121
764
GD1AD
NOMESCO Finland
Thorax CT examination
3.1
7.0
29
98
J02AC01
ATC
fluconazole; systemic
1.9
6.9
115
719
D46.2
ICD-10 Finland
Refractory anaemia with excess of blasts [RAEB]
40.9
6.8
8
*
1XX02, ,
NOMESCO Finland
40.9
6.8
8
*
L01XX52
ATC
venetoclax; oral
23.0
6.7
9
*
L04AA06
ATC
mycophenolic acid; systemic
7.6
6.5
14
19
9891/3-C42.1
ICD-O-3
Acute monocytic leukemia of bone marrow
71.1
6.4
7
*
1DB06, ,
NOMESCO Finland
71.1
6.4
7
*
ZX112
NOMESCO Finland
Subcutaneous
5.4
6.4
18
35
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.9
6.3
106
662
TPX15
NOMESCO Finland
Removal of vascular injection port
18.4
6.3
9
5
C94.7
ICD-10 Finland
Other specified leukaemias
+∞
6.3
6
*
J05AX18
ATC
letermovir; oral
+∞
6.3
6
*
C92.7
ICD-10 Finland
Other myeloid leukaemia
+∞
6.3
6
*
328
Kela drug reimbursment
Nilotinib
+∞
6.3
6
*
C95.2
ICD-10 Finland
Subacute leukemia of unspecified cell type
+∞
6.3
6
*
B74
ICPC
Malignant neoplasm blood other
+∞
6.3
6
*
L01EA03
ATC
nilotinib; oral
+∞
6.3
6
*
122
Kela drug reimbursment
Aplastic anaemia
27.2
6.3
8
*
EBA15
NOMESCO Finland
Extraction of multiple teeth
3.8
6.0
18
49
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
100
50
27.92
136.03
5.3
1.5
—
—
—
0
0
191
313
12.64
127.61
16.2
4.1
402.74
240.70
u/l
2.82
185
297
89
58
20.43
106.48
1.3
1.2
—
—
—
0
0
81
50
20.95
99.21
1.4
1.2
105.04
102.63
u/ml
—
24
8
81
57
18.34
92.70
1.3
1.2
247.24
257.60
u/ml
0.05
51
25
75
49
19.36
89.02
12.6
7.1
272.50
140.13
iu/ml
—
16
8
133
252
8.03
73.68
7.4
3.0
58.91
68.85
e9/l
1.82
103
201
155
346
7.40
73.25
9.0
3.1
1.65
1.76
%
0.66
146
312
77
76
12.81
71.50
1.7
1.8
—
—
—
0
0
69
66
12.86
65.17
3.8
1.5
—
—
—
0
0
67
66
12.40
61.96
3.5
1.5
—
—
—
0
0
57
45
15.02
60.38
3.7
1.6
—
—
—
0
0
57
45
15.02
60.38
3.7
1.6
—
—
—
0
0
146
407
5.53
51.85
12.2
3.8
0.80
0.81
mmol/l
0.80
139
384
138
369
5.61
51.37
15.1
5.6
1.12
1.08
mmol/l
0.80
133
337
52
50
12.10
48.49
3.9
1.5
—
—
—
0
0
42
31
15.32
45.88
2.0
1.5
—
—
—
0
0
42
31
15.32
45.88
2.0
1.5
—
—
—
0
0
74
130
7.00
42.38
1.6
2.2
1.57
1.46
g/l
0.32
55
114
173
684
4.11
36.79
9.9
2.7
311.04
6328.24
umol/l
2.65
167
588
92
226
5.21
36.58
3.6
2.8
63.57
66.31
g/l
2.51
87
202
31
0
+∞
32.84
1.0
0.0
—
—
—
0
0
33
29
12.50
32.28
4.5
1.7
—
—
—
0
0
33
30
12.07
31.58
2.3
1.3
—
—
—
0
0
35
5
77.62
31.53
1.1
1.0
—
—
—
0
0
34
36
10.38
29.33
4.4
1.6
—
—
—
0
0
125
452
3.79
29.10
3.9
1.9
—
—
—
0
0
35
39
9.89
29.10
2.1
1.3
—
—
—
0
0
40
57
7.82
27.32
7.5
1.2
1.52
2.80
e6/l
1.02
29
44
40
57
7.82
27.32
7.5
1.3
7.80
593.67
e6/l
0.96
30
45
38
51
8.26
27.30
1.5
1.5
—
—
—
0
0
224
1261
3.28
24.10
25.5
5.5
2.08
2.86
%
7.60
218
1179
227
1298
3.25
23.57
25.7
5.7
31.39
27.72
%
2.81
220
1219
93
316
3.67
23.18
2.6
1.8
—
—
—
0
0
92
318
3.60
22.26
2.7
1.9
—
—
—
0
0
70
201
4.13
22.13
3.6
1.5
—
—
—
0
0
129
559
3.11
21.45
6.0
1.7
3.52
1.38
mg/l
1.46
114
438
34
53
7.02
21.34
7.4
1.2
3.46
3.88
mmol/l
1.38
34
47
217
1283
2.91
19.85
24.2
5.4
49.50
57.18
%
8.58
212
1204
244
1552
3.03
19.18
44.1
9.2
3.28
4.15
e9/l
1.64
226
1350
30
22
14.83
18.14
1.8
1.2
—
—
—
0
0
206
1235
2.69
17.51
19.4
6.3
1.20
1.21
mmol/l
2.18
197
1124
28
19
15.94
17.47
1.2
1.1
—
—
—
0
0
28
44
6.84
17.38
1.5
1.5
—
—
—
0
0
26
39
7.14
16.82
1.5
1.5
—
—
—
0
0
22
8
29.26
16.71
2.2
1.1
—
—
—
0
0
218
1363
2.67
16.70
21.8
7.2
1.20
1.21
mmol/l
1.26
189
1166
29
24
13.10
16.68
4.8
2.3
—
—
—
0
0
128
621
2.70
16.51
10.5
2.4
—
—
—
0
0
27
20
14.55
16.29
1.6
2.6
33.44
47.51
%
—
9
13
198
1196
2.57
16.08
10.2
2.7
—
—
—
0
0
26
41
6.78
16.07
1.5
1.5
—
—
—
0
0
190
1148
2.48
15.09
15.6
4.8
33.62
35.37
g/l
3.93
184
1076
35
82
4.64
14.20
2.6
1.2
—
—
—
0
0
23
18
13.61
13.61
4.2
2.7
—
—
—
0
0
23
19
12.89
13.31
1.5
1.8
—
—
—
0
0
23
19
12.89
13.31
1.5
1.8
—
—
—
0
0
36
92
4.26
13.08
2.3
2.8
—
—
—
0
0
12
0
+∞
12.57
12.9
0.0
—
—
—
0
0
24
25
10.24
12.45
5.8
1.7
—
—
—
0
0
24
25
10.24
12.45
5.8
1.7
—
—
—
0
0
24
25
10.24
12.45
5.8
1.7
—
—
—
0
0
21
17
13.08
12.29
6.7
3.6
—
—
—
0
0
22
20
11.68
12.22
1.2
1.2
—
—
—
0
0
23
24
10.19
11.94
1.1
1.2
—
—
—
0
0
33
86
4.14
11.67
4.2
3.2
57.11
141.95
mg/l
0.56
27
69
33
86
4.14
11.67
4.2
3.2
117.65
37.48
mg/l
0.43
27
70
84
386
2.56
11.58
2.3
2.5
31.35
22.52
%
2.18
73
331
32
86
4.00
10.86
4.3
3.1
—
1.32
—
0
9
46
158
3.21
10.83
2.8
1.7
—
—
—
0
0
34
97
3.78
10.62
2.8
1.8
—
—
—
0
0
171
1095
2.13
10.56
4.5
2.7
520.28
132.10
ug/l
7.52
162
1001
36
108
3.61
10.46
6.1
1.9
—
—
—
0
0
120
675
2.20
10.29
2.1
2.2
3.07
3.07
mg/l
0.00
104
589
220
1577
2.12
9.78
15.1
5.1
6.78
6.73
mmol/l
0.12
215
1480
16
12
13.92
9.77
7.6
1.9
—
—
—
0
0
16
12
13.92
9.77
7.6
1.9
—
—
—
0
0
16
13
12.85
9.45
7.6
1.8
—
—
—
0
0
9
0
+∞
9.41
4.4
0.0
—
—
—
0
0
32
96
3.58
9.29
2.3
2.4
1.79
0.72
g/l
0.31
27
84
16
14
11.93
9.16
7.8
1.8
—
—
—
0
0
16
14
11.93
9.16
7.8
1.8
—
—
—
0
0
34
110
3.32
8.79
2.2
2.2
—
—
—
0
0
24
63
4.02
8.40
1.1
1.6
223.60
262.38
miu/ml
—
5
29
15
14
11.15
8.37
1.1
1.0
—
—
—
0
0
16
18
9.27
8.13
2.1
1.1
—
—
—
0
0
13
10
13.46
7.94
8.3
1.4
—
—
—
0
0
181
1269
1.91
7.88
17.7
15.1
1.30
1.29
inr
0.06
56
362
130
826
1.93
7.55
5.1
2.6
55.30
62.68
u/l
0.52
124
762
7
0
+∞
7.31
5.7
0.0
—
—
—
0
0
11
8
14.15
6.93
3.3
1.3
—
—
%
—
0
0
12
12
10.32
6.58
3.7
1.4
—
—
—
0
0
12
12
10.32
6.58
3.7
1.4
—
—
—
0
0
12
13
9.52
6.34
3.7
1.5
—
—
—
0
0
12
13
9.52
6.34
3.7
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
24
77
3.28
6.30
5.7
2.3
0.22
0.41
u/ml
2.40
17
41
18
49
3.82
6.00
8.3
3.0
48.44
57.82
%
1.15
18
49
129
873
1.77
5.81
5.4
3.4
2.31
2.35
mmol/l
3.09
121
765
15
27
5.76
5.75
1.3
1.4
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
9
7
13.16
5.61
1.4
1.0
70.89
142.29
%
—
9
7
13
21
6.39
5.44
1.8
1.2
—
—
—
0
0
45
218
2.23
5.33
5.9
3.6
0.48
1.54
mmol/l
1.08
39
156
147
1059
1.68
5.14
2.1
2.0
90.13
93.50
pmol/l
0.38
104
544
19
60
3.29
5.12
1.2
1.3
—
—
—
0
0
57
308
2.02
5.11
10.6
8.8
1.40
1.05
mmol/l
0.37
43
243
8
6
13.61
5.10
1.3
1.5
—
—
—
0
0
217
1754
1.66
4.67
5.5
4.7
26.00
2401.73
e6/l
—
5
30
22
81
2.83
4.61
2.2
1.9
18.76
19.29
iu/l
0.03
17
70
7
5
14.25
4.59
2.0
1.8
—
—
—
0
0
51
276
2.00
4.54
19.0
4.3
1.41
1.77
mmol/l
0.23
43
208
20
71
2.93
4.47
1.2
1.2
—
—
—
0
0
9
12
7.67
4.38
1.6
2.2
87.67
102.08
%
—
9
12
9
12
7.67
4.38
1.1
1.3
—
—
—
0
0
33
155
2.25
4.22
1.5
1.4
—
—
—
0
0
18
63
2.96
4.13
5.1
1.4
—
—
—
0
0
136
1005
1.59
4.06
5.5
3.3
—
—
—
0
0
9
14
6.57
4.01
1.4
1.3
—
—
—
0
0
20
77
2.70
3.88
1.2
1.5
—
—
—
0
0
15
49
3.16
3.85
2.1
1.2
—
—
—
0
0
80
524
1.69
3.84
2.0
1.7
1196.17
1181.65
nmol/l
0.05
69
394
9
15
6.13
3.84
1.4
1.3
—
—
—
0
0
53
309
1.85
3.79
10.0
8.7
4.93
5.06
kpa
0.49
48
295
13
34
3.93
3.73
6.5
1.5
—
—
—
0
0
79
521
1.67
3.69
5.0
4.0
594.99
228.21
ng/l
0.43
69
423
13
35
3.82
3.63
6.5
1.5
—
—
—
0
0
13
35
3.82
3.63
6.5
1.5
—
—
—
0
0
13
35
3.82
3.63
6.5
1.5
—
—
—
0
0
13
35
3.82
3.63
6.5
1.5
—
—
—
0
0
18
68
2.74
3.62
2.3
1.9
9.38
7.37
u/l
0.32
11
57
116
846
1.56
3.58
3.4
3.3
1181.11
1425.42
ng/l
0.44
101
714
13
36
3.71
3.53
6.5
1.5
—
—
—
0
0
6
6
10.15
3.51
1.0
1.0
—
—
—
0
0
6
6
10.15
3.51
1.2
1.0
—
—
—
0
0
52
309
1.81
3.49
10.2
8.7
10.94
11.89
kpa
0.99
47
297
16
58
2.85
3.47
1.4
1.3
—
—
—
0
0
16
58
2.85
3.47
1.4
1.3
—
—
—
0
0
13
37
3.61
3.44
1.0
1.1
—
—
—
0
0
13
42
3.18
3.40
1.1
1.1
—
—
—
0
0
9
18
5.10
3.39
1.4
1.3
—
—
—
0
0
8
15
5.43
3.21
2.5
1.1
—
—
—
0
0
7
11
6.47
3.20
14.6
4.5
245.57
228.27
u/l
—
7
11
79
564
1.52
2.60
1.6
1.8
399.01
435.92
pmol/l
0.61
69
472
5
7
7.23
2.55
1.2
2.3
—
—
—
0
0
221
1922
1.43
2.50
5.6
4.1
18.79
12.09
mm/h
4.63
211
1760
19
89
2.20
2.50
33.1
4.6
1.18
1.54
mg/l
1.73
19
80
6
12
5.07
2.41
1.7
1.1
—
—
—
0
0
9
27
3.40
2.41
1.0
1.4
—
—
—
0
0
101
769
1.45
2.40
5.6
3.3
1.04
0.50
e6/l
0.48
84
581
129
1039
1.39
2.21
4.1
4.1
54.54
37.05
ng/l
0.34
103
744
32
190
1.76
2.19
6.7
2.8
66.26
61.18
ml/min/173m2
0.27
19
79
6
14
4.34
2.16
2.0
1.1
—
—
—
0
0
13
56
2.37
2.07
2.7
2.3
16.44
16.26
%
—
5
27
7
20
3.55
2.06
1.4
1.8
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
15
4.05
2.04
1.7
1.2
—
—
—
0
0
11
44
2.55
2.03
1.0
2.0
—
—
—
0
0
39
254
1.60
1.92
3.4
2.2
28.97
32.25
u/l
0.36
34
208
5
12
4.21
1.83
15.4
2.6
—
—
—
0
0
5
12
4.21
1.83
15.4
2.6
—
—
—
0
0
274
2910
0.70
1.77
69.7
21.6
3.94
4.50
e12/l
25.41
268
2821
274
2909
0.70
1.76
71.5
21.8
35.47
40.21
%
26.31
259
2724
8
30
2.71
1.73
2.6
2.3
—
—
—
0
0
5
13
3.89
1.72
2.2
1.2
—
—
—
0
0
236
2557
0.75
1.64
5.0
4.9
2.59
2.68
mmol/l
0.67
222
2340
17
91
1.91
1.63
1.5
1.6
—
132.00
—
0
5
12
56
2.18
1.63
1.1
1.3
—
—
—
0
0
5
15
3.37
1.53
1.6
1.0
—
—
—
0
0
6
21
2.89
1.51
1.7
3.2
12.92
84.99
u/ml
—
6
21
9
37
2.47
1.49
1.1
1.4
—
—
—
0
0
6
22
2.76
1.44
1.0
1.1
—
—
—
0
0
0
37
0.00
1.35
0.0
1.1
—
2.79
—
0
11
232
2496
0.78
1.33
4.6
4.4
1.31
1.44
mmol/l
4.66
216
2279
5
18
2.80
1.29
1.0
1.0
—
—
—
0
0
6
25
2.42
1.25
1.0
1.2
—
—
—
0
0
6
25
2.42
1.25
1.0
1.2
—
—
—
0
0
149
1309
1.25
1.20
3.4
3.9
0.00
0.00
estimate
-0.00
24
225
6
26
2.33
1.19
1.0
1.2
—
—
—
0
0
6
26
2.33
1.19
1.0
1.2
—
—
—
0
0
6
26
2.33
1.19
1.0
1.2
—
—
—
0
0
7
30
2.36
1.13
1.0
1.2
—
—
—
0
0
146
1294
1.22
1.06
4.6
5.2
0.00
0.00
estimate
-0.00
24
231
9
46
1.98
1.04
1.1
1.2
—
—
—
0
0
5
23
2.19
0.98
1.0
1.0
—
—
—
0
0
145
1293
1.21
0.97
3.4
3.9
0.00
0.00
estimate
0.50
25
255
66
793
0.79
0.93
4.1
4.4
21.12
21.52
%
0.07
32
373
8
42
1.93
0.89
1.3
1.6
—
—
—
0
0
222
2358
0.83
0.86
4.7
4.5
2.09
1.94
mu/l
1.10
207
2123
56
457
1.27
0.85
5.7
3.1
1.47
2.07
e6/l
0.43
34
255
235
2478
0.83
0.81
5.9
4.6
6.02
6.01
mmol/l
0.05
218
2242
40
315
1.31
0.79
1.6
1.4
—
—
—
0
0
6
34
1.78
0.76
1.0
1.0
—
—
—
0
0
9
53
1.72
0.76
1.9
1.3
—
—
—
0
0
9
55
1.65
0.74
1.1
1.2
—
—
—
0
0
9
55
1.65
0.74
1.1
1.2
—
1.08
—
0
5
239
2509
0.84
0.74
5.1
4.4
4.38
4.55
mmol/l
1.71
228
2315
5
25
2.01
0.73
1.8
3.0
—
—
—
0
0
7
42
1.68
0.69
1.9
3.4
12.14
35.14
u/ml
—
7
42
5
27
1.86
0.68
1.8
1.3
136960.00
31032.86
e6/l
—
5
14
228
2397
0.85
0.68
5.3
5.8
39.37
40.32
mmol/mol
0.77
214
2221
5
28
1.80
0.66
1.0
1.1
—
—
—
0
0
11
70
1.59
0.66
1.1
1.1
—
—
—
0
0
5
29
1.73
0.64
1.0
1.1
—
—
—
0
0
5
29
1.73
0.64
2.0
1.3
188.20
327.80
u/l
—
5
29
51
602
0.82
0.62
1.3
1.4
2.69
1.21
u/ml
0.39
13
151
111
1004
1.16
0.59
3.1
4.1
—
—
—
0
0
49
573
0.83
0.55
3.0
2.9
0.58
0.81
ug/l
1.76
33
362
269
2774
0.85
0.53
35.3
10.2
29.78
26.06
u/l
2.48
262
2667
11
76
1.46
0.48
2.1
1.7
—
—
—
0
0
11
153
0.71
0.46
1.3
1.2
75.83
117.79
iu/ml
—
6
55
5
82
0.60
0.46
1.2
1.5
—
—
—
0
0
5
31
1.62
0.43
1.0
1.3
0.48
0.45
nmol/l
—
5
25
5
31
1.62
0.43
2.6
1.2
—
—
—
0
0
78
705
1.14
0.42
3.6
4.2
0.00
0.00
estimate
-0.00
24
229
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
46
402
1.17
0.39
1.1
1.3
2.91
10.36
u/ml
1.70
16
146
9
66
1.37
0.38
1.1
1.3
—
8.73
—
0
13
36
310
1.18
0.37
3.9
4.5
28.73
31.84
%
0.93
30
203
6
43
1.40
0.35
1.0
1.1
—
—
—
0
0
36
312
1.17
0.35
10.4
8.0
—
—
—
0
0
34
297
1.16
0.31
4.1
4.4
3.67
59.43
ug/l
1.29
26
246
269
2634
1.10
0.27
52.0
14.9
27.88
24.77
mg/l
0.67
253
2071
8
66
1.22
0.27
1.3
1.4
0.89
0.76
nmol/l
—
8
55
52
477
1.11
0.24
5.9
2.9
0.62
1.01
e6/l
1.02
31
274
16
134
1.20
0.23
36.8
3.8
1.41
1.14
%
0.70
16
134
0
10
0.00
0.21
0.0
1.2
—
7.96
—
0
10
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
314.60
—
0
5
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
156
1608
0.94
0.18
3.8
3.0
—
—
—
0
0
17
195
0.87
0.18
1.6
1.7
—
—
—
0
0
22
247
0.88
0.18
1.6
2.2
—
—
—
0
0
19
167
1.15
0.17
2.6
2.5
—
16.50
—
0
8
49
458
1.08
0.16
1.9
1.5
—
—
—
0
0
237
2408
0.95
0.15
5.3
4.0
1.48
1.27
mmol/l
3.56
223
2195
17
150
1.14
0.14
1.4
1.3
—
55.44
—
0
12
11
93
1.19
0.14
1.4
1.2
—
—
—
0
0
11
95
1.16
0.12
1.4
1.2
—
—
—
0
0
236
2389
0.96
0.10
34.1
13.7
81.57
79.43
ml/min/173m2
0.60
201
1963
28
263
1.07
0.08
6.6
3.4
—
—
—
0
0
78
802
0.96
0.08
3.7
3.8
10.56
10.53
mg/mmol
0.00
53
512
7
80
0.87
0.07
1.4
1.5
—
—
—
0
0
11
122
0.90
0.07
2.3
2.1
—
—
—
0
0
8
91
0.88
0.07
2.4
1.9
—
—
—
0
0
11
99
1.11
0.06
1.7
2.1
—
—
—
0
0
13
141
0.92
0.05
1.5
1.3
—
—
—
0
0
14
130
1.08
0.04
37.0
3.9
0.91
0.65
%
0.85
14
130
171
1694
1.02
0.04
4.8
3.2
79.51
48.71
u/l
2.13
160
1576
41
422
0.97
0.04
1.3
1.3
14.35
30.87
iu/ml
2.11
12
132
14
141
0.99
0.00
1.1
1.0
—
—
—
0
0
22
224
0.98
0.00
1.6
2.1
—
—
—
0
0
5
58
0.86
-0.00
1.2
1.1
—
—
—
0
0
5
50
1.00
-0.00
2.2
1.2
4712.80
23679.21
e6/l
—
5
34
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
193
1930
1.00
-0.00
4.0
3.7
14.95
14.82
pmol/l
0.28
178
1720
0
9
0.00
-0.00
0.0
1.0
—
7.86
—
0
9
0
5
0.00
-0.00
0.0
4.8
—
60.30
—
0
5
0
9
0.00
-0.00
0.0
8.1
—
—
—
0
0
5
55
0.91
-0.00
1.8
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_LEUKAEMIA_NAS – Leukaemia of unspecified cell type
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).